4. Characteristics of identified studies: outcomes*.
| Outcome domain | Outcome | Number of studies* | Percentage of studies* |
| Overall | 287 | ||
| Clinical | |||
| SARS‐CoV‐2 infection, any | 80 | 27.9 | |
| SARS‐CoV‐2 infection, asymptomatic | 19 | 6.6 | |
| SARS‐CoV‐2 infection, symptomatic | 19 | 6.6 | |
| SARS‐CoV‐2 infection, hospitalisation | 44 | 15.3 | |
| SARS‐CoV‐2 infection, mortality | 36 | 12.5 | |
| Safety | |||
| Any adverse events | 126 | 43.9 | |
| Serious adverse events | 54 | 18.8 | |
| Disease‐specific adverse events | 50 | 17.4 | |
| Immunogenicity | |||
| Seroconversion, binding Ab | 179 | 62.2 | |
| Seroconversion, neutralising Ab | 49 | 17.1 | |
| IgG titres | 175 | 61.0 | |
| IgA titres | 7 | 2.4 | |
| IgM titres | 9 | 3.1 | |
| Neutralising Ab titres | 64 | 22.3 | |
| B‐cell response | 4 | 1.4 | |
| T‐cell response | 37 | 12.9 | |
| Abbreviations: Ab: antibody; Ig: immunoglobulin, SARS‐CoV‐2: severe acute respiratory syndrome coronavirus 2 | |||
*Excluding studies on pregnant and lactating women.